Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

Annals of Internal Medicine

Volumn 132, Issue 12, 2000, Pages 947-954

  White, Barbara ^c   Moore, Wendy C ^a   Wigley, Fredrick M ^b   Xiao, Hui Qing ^b   Wise, Robert A ^b  

^a Division of Pulmonary and Critical Care Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; LUNG ALVEOLITIS; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCLERODERMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034691244     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-12-200006200-00004     Document Type: Article

References (31)

1. Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, furst DE, eds. Systemic Sclerosis. Baltimore: Williams & Wilkins; 1996:51-64.
2. Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM. et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 1991;144(3 Pt 1):706-13.
3. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88:470-6.
4. Wallaert B, Hatron PY, Grosbois JM, Tonnel AB, Devulder B, Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function Am Rev Respir Dis. 1986;133:574-80.
5. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med. 1996;154(2 Pt 1) 400-6.
6. Rossi GA, Bitterman PB, Rennard SI, Ferrans VJ, Crystal RG. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis. 1985;131:612-7.
7. Chanez P, Lacoste JY, Guillot B, Giron J, Barneon G, Enander I, et al. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung. Am Rev Respir Dis. 1993;147(6 Pt 1):1497-502.
8. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993; 20:838-44.
9. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994;37:1290-6.
10. Akesson A, Scheja A, Lundin A, Wollheim F. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994;37:729-35.
11. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum. 1998;41:1215-20.
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostics and Therapeutics Criteria Committee. Arthritis Rheum. 1980;23:581-90.
13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
14. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995;38:351-60.
15. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Cnt Care Med. 1995;152:1107-36.
16. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2185-98.
17. Goldman HI, Becklake MR. Respiratory function tests. Normal values at median altitudes and the prediction of normal results. Am Rev Respir Dis. 1959;79:457-67.
18. Burrows B, Kasik JE, Niden AH, Barclay WR. Clinical usefulness of the single-breath pulmonary diffusing capacity test. Am Rev Respir Dis. 1961;84: 789-806.
19. + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum. 1999;42:1168-78.
20. Merchant RK, Schwartz DA, Helmers RA, Dayton CS, Hunninghake GW. Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis. 1992;146:448-53.
21. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society. 1972;34:187-220.
22. Becklake MR, Permutt S. Evaluation of tests of lung function for "screening" for early detection of chronic obstructive lung disease. In: Macklem PT, Permutt S, eds. The Lung in the Transition between Health and Disease. New York: Marcel Dekker; 1979:345-87.
23. Silver RM, Metcalf JF, Stanley JH, LeRoy EC. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum. 1984;27: 1254-62.
24. Wells AU, Hansell DM, Rubens MB, Cullinan P, Haslam PL, Black CM, et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med. 1994;150:462-8.
25. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis Arthritis Rheum. 1994;37:1283-9.
26. Struck RF, Alberts DS, Home K, Phillips JG, Peng YM, Roe DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 1987;47:2723-6.
27. Lacki JK, Mackiewicz SH, Wiktorowkz KE. Contrasting effect of oral and intravenous cyclophosphamide treatment on phenotypes of human peripheral blood lymphocytes. Arch Immunol Ther Exp (Warsz). 1994;42:291-4.
28. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187-98.
29. O'Donnell K, Keogh B, Cantin A, Crystal RG. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1987;136:288-92.
30. Peters-Golden M, Wise RA, Hochberg MC, Stevens MB, Wigley FM. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med. 1984;77:1027-34.
31. Tashkin DP, Clements PJ, Wright RS, Gong H Jr, Simmons MS, Lachenbruch PA, et al. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. Chest. 1994;105: 489-95.